Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Boehringer Ingelheim
Dow
Colorcon
Moodys

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Aldoxorubicin

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Aldoxorubicin?

Aldoxorubicin is an investigational drug.

There have been 16 clinical trials for Aldoxorubicin. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2014.

The most common disease conditions in clinical trials are Sarcoma, Lung Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are CytRx, NantKwest, Inc., and [disabled in preview].

There are two US patents protecting this investigational drug and ten international patents.

Recent Clinical Trials for Aldoxorubicin
TitleSponsorPhase
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNantKwest, Inc.Phase 2
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerNantKwest, Inc.Phase 2
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.NantKwest, Inc.Phase 1/Phase 2

See all Aldoxorubicin clinical trials

Clinical Trial Summary for Aldoxorubicin

Top disease conditions for Aldoxorubicin
Top clinical trial sponsors for Aldoxorubicin

See all Aldoxorubicin clinical trials

US Patents for Aldoxorubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Aldoxorubicin   Start Trial Anthracycline formulations CytRx Corporation (Los Angeles, CA)   Start Trial
Aldoxorubicin   Start Trial Combinations of albumin-based drug delivery systems KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Aldoxorubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Aldoxorubicin Australia 2013359048 2032-12-13   Start Trial
Aldoxorubicin Canada 2894548 2032-12-13   Start Trial
Aldoxorubicin European Patent Office 2931042 2032-12-13   Start Trial
Aldoxorubicin Hong Kong 1209973 2032-12-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Dow
Harvard Business School
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.